Enlivex Therapeutics Completes Phase II COVID-19 Trial Enrollment
Ticker: ENLV · Form: 6-K · Filed: Jul 28, 2025 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial, covid-19, drug-development
TL;DR
Enlivex finished enrolling all 134 patients in its Phase II COVID-19 trial for Allocetra.
AI Summary
On July 28, 2025, Enlivex Therapeutics Ltd. announced that all 134 patients in the Phase II stage of its randomized, controlled trial for its drug Allocetra have completed the study. The trial is investigating the drug's efficacy in treating severe COVID-19 patients.
Why It Matters
The completion of patient enrollment in this Phase II trial is a crucial step towards potentially validating Allocetra as a treatment for severe COVID-19, impacting future treatment options and the company's development pipeline.
Risk Assessment
Risk Level: medium — Clinical trial progress is a key indicator, but the outcome of the trial and subsequent regulatory approvals are still uncertain.
Key Numbers
- 134 — Patients Enrolled (All patients in the Phase II trial for Allocetra have completed the study.)
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Allocetra (drug) — Investigational drug
- July 28, 2025 (date) — Announcement date
- 134 (patient_count) — Number of patients enrolled in Phase II trial
FAQ
What is the primary purpose of the Phase II trial mentioned in the filing?
The Phase II trial is investigating the efficacy of Allocetra in treating severe COVID-19 patients.
What is the name of the drug being studied?
The drug being studied is Allocetra.
How many patients were enrolled in the Phase II trial?
All 134 patients enrolled in the Phase II trial have completed the study.
On what date was this announcement made?
The announcement was made on July 28, 2025.
What is the company's principal executive office location?
The company's principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 28, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).